Edition:
United States

Spark Therapeutics Inc (ONCE.OQ)

ONCE.OQ on NASDAQ Stock Exchange Global Select Market

46.37USD
15 Dec 2017
Change (% chg)

$1.16 (+2.57%)
Prev Close
$45.21
Open
$45.39
Day's High
$46.38
Day's Low
$45.09
Volume
587,987
Avg. Vol
221,331
52-wk High
$91.75
52-wk Low
$41.06

Chart for

About

Spark Therapeutics, Inc. is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a... (more)

Overall

Beta: --
Market Cap(Mil.): $1,715.94
Shares Outstanding(Mil.): 37.01
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 198.20 16.04
EPS (TTM): -- -- --
ROI: -- -11.76 34.69
ROE: -- -36.72 15.46

BRIEF-Spark Therapeutics and Pfizer amend license agreement for investigational SPK-9001 in hemophilia B

* Spark Therapeutics and Pfizer amend license agreement for investigational SPK-9001 in hemophilia B

Nov 07 2017

BRIEF-Spark Therapeutics reports Q3 loss per share $1.90

* Spark Therapeutics Inc reports third quarter 2017 financial results and recent business progress

Nov 07 2017

FDA panel backs gene therapy for rare form of blindness

Spark Therapeutics Inc's experimental gene therapy for a rare form of blindness improves vision and should be approved, advisers to the Food and Drug Administration concluded on Thursday, paving the way for the first U.S. gene therapy for an inherited disease.

Oct 12 2017

UPDATE 2-U.S. FDA panel backs gene therapy for rare form of blindness

Oct 12 Spark Therapeutics Inc's experimental gene therapy for a rare form of blindness improves vision and should be approved, advisers to the Food and Drug Administration concluded on Thursday, paving the way for the first U.S. gene therapy for an inherited disease.

Oct 12 2017

FDA panel votes in favor of Spark's blindness gene therapy

Oct 12 Spark Therapeutics Inc's experimental gene therapy for a rare form of blindness improves vision and should be approved, advisers to the Food and Drug Administration concluded on Thursday, paving the way for the first U.S. gene therapy for an inherited disease.

Oct 12 2017

Spark gene therapy improves vision, at least in short term: FDA

Spark Therapeutics Inc's experimental gene therapy for a rare inherited form of blindness improves vision, though it is unclear whether the benefit lasts over time, according to a preliminary review by the U.S. Food and Drug Administration.

Oct 10 2017

UPDATE 2-Spark gene therapy improves vision, at least in short term-FDA

Oct 10 Spark Therapeutics Inc's experimental gene therapy for a rare inherited form of blindness improves vision, though it is unclear whether the benefit lasts over time, according to a preliminary review by the U.S. Food and Drug Administration.

Oct 10 2017

Spark's blindness gene therapy reviewed by U.S. FDA

Oct 10 Spark Therapeutics Inc's experimental gene therapy for a rare inherited form of blindness is effective, though it is unclear whether the benefit lasts over time, according to a preliminary review by the U.S. Food and Drug Administration.

Oct 10 2017

BRIEF-Spark Therapeutics enters into licensing agreement with Genethon

* Spark Therapeutics enters into licensing agreement with Genethon

Sep 20 2017

BRIEF-Spark Therapeutics announces closing of public offering

* Spark Therapeutics announces closing of public offering Source text for Eikon: Further company coverage:

Aug 09 2017

Earnings vs. Estimates